Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859949 | 0.88 | TSHR (0.35) | TRPA1CA1CA2ADRA1ACA12 | |
| SCHEMBL24592151 | 0.85 | CYP11B2 (0.40) | CYP11B2CYP11B1CA1CA2ADRA1A | |
| SCHEMBL13859947 | 0.83 | CA12 (0.33) | CYP11B2CYP11B1CA1CA2ADRA1A | |
| SCHEMBL13859957 | 0.82 | CYP11B1 (0.34) | CYP11B2CYP11B1METCYP19A1 | |
| SCHEMBL13859951 | 0.82 | CYP11B1 (0.37) | CYP11B2CYP11B1CA1CA2CA12 | |
| SCHEMBL31586332 | 0.78 | TRPA1 (0.50) | TRPA1CYP11B2CYP11B1CA1CA2 | |
| SCHEMBL1953522 | 0.78 | CYP11B2 (0.39) | TRPA1CYP11B2CYP11B1CA1CA2 | |
| SCHEMBL283346 | 0.78 | TRPA1 (0.50) | TRPA1CYP11B2CYP11B1CA1CA2 | |
| SCHEMBL17936813 | 0.74 | — | — | |
| SCHEMBL2779620 | 0.74 | GSK3A (0.39) | CA1CA2CA12CA9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-11678498-B2 | Organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-06-13 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-06-08 | — | — | US | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-5089496-A | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| US-5089496-A | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| WO-1990013548-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| WO-1990013548-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| EP-0396083-A1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORPORATION (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0396083-A1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORPORATION (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0330673-A1 | BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0270818-A1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0270818-A1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988003138-A1 | BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | TRPA1 4875/4885CYP11B2 655/4885CYP11B1 1023/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | TRPA1 4875/4885CYP11B2 655/4885CYP11B1 1023/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | TRPA1 4875/4885CYP11B2 655/4885CYP11B1 1023/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | TRPA1 4788/4885CYP11B2 2642/4885CYP11B1 2447/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | TRPA1 4707/4885CYP11B2 4218/4885CYP11B1 3601/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | TRPA1 4788/4885CYP11B2 2642/4885CYP11B1 2447/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | TRPA1 4875/4885CYP11B2 655/4885CYP11B1 1023/4885 |
| US-11026914-B2 | Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brain tumor | DDOST, DAD1, PHGDH | TRPA1 4871/4885CYP11B2 2013/4885CYP11B1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.